Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Oligometastatic Prostate Cancer × zimberelimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 8 Carcinoma, Non-Small-Cell Lung 8 Stomach Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Triple Negative Breast Neoplasms 3 Recurrence 3 Pancreatic Neoplasms 3 Advanced Solid Tumors 3 Solid Tumor 2 Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2 Lung Neoplasms 2 Esophageal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Adenocarcinoma Of Esophagus 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Urothelial Bladder Carcinoma 1 Urinary Bladder Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Solid Tumors 1 Solid Tumor, Unspecified, Adult 1 Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1 Pharyngeal Neoplasms 1

Interventions

Radiosurgery 2 Androgen Antagonists 2 zimberelimab 1 quemliclustat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05915442 2025-05-20

SBRT-AMICO

Columbia University

Phase 2 Recruiting

Oligometastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡